- Home
- MINE vs PRQR Comparison
MINE vs PRQR Comparison
Compare MINE & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MINE | PRQR |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | Canada | Netherlands |
| Employees | 9 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.5M | 166.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MINE | PRQR |
|---|---|---|
| Price | $2.37 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 26.1K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.16 | $1.33 |
| 52 Week High | $4.45 | $3.10 |
Technical Indicators
Market Signals| Indicator | MINE | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 52.17 |
| Support Level | $2.16 | $1.39 |
| Resistance Level | $3.21 | $2.03 |
| Average True Range (ATR) | 0.19 | 0.19 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 40.63 | 58.73 |
Price Performance
Historical ComparisonAbout MINE Mayfair Gold Corp. Common Shares
Mayfair Gold Corp is a mineral exploration company that is engaged in the acquisition and exploration of mineral properties. It has one material mineral property, the Fenn-Gib Gold Property, located in the Guibord, Munro, Michaud, and McCool Townships in northeast Ontario, which is in the exploration stage.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.